Charles O'Keeffe B.'s Insider Trades & SAST Disclosures
Charles O'Keeffe B.'s most recent trade in Catalyst Pharmaceuticals Inc was a trade of 4,000 Common Stock, par value $0.001 per share done . Disclosure was reported to the exchange on Feb. 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Charles O'Keeffe B..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 4,000 | 732,470 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 4,000 | 208,274 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,333 | 728,470 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,333 | 212,274 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 40,000 | 213,607 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.01 per share. | 09 Dec 2024 | 40,000 | 727,137 (0%) | 0% | 4.0 | 160,400 | Common Stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 1,413 | 253,607 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 1,413 | 687,137 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 23,248 | 252,179 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 2,841 | 255,020 | - | - | Restricted stock units | |
| Catalyst Pharmaceuticals Inc | Charles O'Keeffe B. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 685,724 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | B. Charles O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 4,000 | 228,931 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles O'Keeffe B. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 02 Jan 2024 | 60,000 | 681,724 (0%) | 0% | 1.1 | 67,800 | Common Stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 60,000 | 232,931 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 1,333 | 621,724 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | O'Keeffe Charles B. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 1,333 | 292,931 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | B. O'Keeffe Charles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 29,524 | 290,024 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 4,240 | 294,264 | - | - | Restricted stock units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 4,000 | 620,391 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 4,000 | 260,500 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2023 | 50,000 | 264,500 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.79 per share. | 24 Jan 2023 | 50,000 | 616,391 (0%) | 0% | 0.8 | 39,500 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 15,000 | 310,500 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 4,000 | 314,500 | - | - | Restricted stock units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 1,334 | 566,391 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 1,334 | 295,500 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Sale of securities on an exchange or to another person at price $ 16.04 per share. | 15 Nov 2022 | 87,985 | 565,057 (0%) | 0% | 16.0 | 1,411,015 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.53 per share. | 18 Aug 2022 | 40,000 | 653,042 (0%) | 0% | 2.5 | 101,200 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2022 | 40,000 | 296,834 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 12,000 | 336,834 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2021 | 20,000 | 324,834 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 1,333 | 613,042 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 1,333 | 304,834 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2021 | 50,000 | 306,167 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.12 per share. | 16 Aug 2021 | 50,000 | 611,709 (0%) | 0% | 3.1 | 156,000 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 1,333 | 561,709 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 1,333 | 326,167 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Charles B. O'Keeffe | Director | Purchase of securities on an exchange or from another person at price $ 2.99 per share. | 30 Sep 2020 | 7,000 | 560,376 (0%) | 0% | 3.0 | 20,930 | Common stock, par value $0.001 per share |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges